With $70M A round, Takeda deal, 5AM’s Ensoma aims for accessible cell and gene therapies via empty adenoviral vectors
Emerging Company Profile: Ensoma is taking on ex vivo HSC therapies
Launched with a $70 million series A round and a Takeda deal in hand, Ensoma is the latest company focused on broadening access to cell and gene therapies, leveraging high-capacity vectors to develop one-time, off-the-shelf treatments.
Ensoma is betting its genome-free adenoviral vectors, which can carry up to 35 kb of cargo, will bring engineered hematopoietic stem cell (HSC) therapies to larger indications and lower resourced environments by turning complex hospital procedures into simple outpatient ones. ...